AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Recruiting now · Phase 2

Conditions studied: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

In brief

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

Key facts

Study ID
NCT06219941
Run by
AstraZeneca
People needed
226
Starts
2023-12-13
Expected to finish
2027-06-28
Last updated by the study team
2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.